• Antiepileptic and antidepressive polypharmacy in patients with multiple sclerosis. 

      Beiske, Georg; Holmøy, Trygve; Beiske, Antonie Giæver; Johannessen, Svein Ivar; Landmark, Cecilie Johannessen (Multiple sclerosis international;2015, Journal article; Peer reviewed, 2015)
      Objective. Patients with multiple sclerosis (MS) are often suffering from neuropathic pain. Antiepileptic drugs (AEDs) and tricyclic antidepressants (TCAs) are commonly used and are susceptible to be involved in drug ...
    • B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate 

      Høglund, Rune Alexander; Polak, Justyna; Vartdal, Frode; Holmøy, Trygve; Lossius, Andreas Lunde (Multiple sclerosis and related disorders;26, Journal article; Peer reviewed, 2018-08-30)
      Background:B cells may contribute to the immunopathogenesis of multiple sclerosis (MS). Dimethyl fumarate(DMF) has recently been shown to reduce the frequency of memory B cells in blood, but it is not known whetherthe drug ...
    • Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations 

      König, Marton; Lorentzen, Åslaug Rudjord; Torgauten, Hilde Marie; Tran, The Trung; Schikora-Rustad, Stine; Vaage, Eline Benno; Mygland, Åse Daasvand; Wergeland, Stig; Aarseth, Jan Harald; Aaberge, Ingeborg Sundsvalen; Torkildsen, Øivind; Holmøy, Trygve; Berge, Tone; Myhr, Kjell-Morten; Harbo, Hanne-Cathrin Flinstad; Andersen, Jan Terje; Munthe, Ludvig Andre; Søraas, Arne Vasli; Celius, Elisabeth Gulowsen; Vaage, John T.; Lund-Johansen, Fridtjof; Nygaard, Gro Owren (Journal of Neurology, Neurosurgery and Psychiatry;, Peer reviewed; Journal article, 2021-10-20)
      Introduction: The effect of disease-modifying therapies (DMT) on vaccine responses is largely unknown. Understanding the development of protective immunity is of paramount importance to fight the COVID-19 pandemic. Objective: ...
    • Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: The relevance of time since last rituximab infusion and first experience from sporadic revaccinations 

      König, Marton; Lorentzen, Åslaug Rudjord; Torgauten, Hilde Marie; Tran, Trung; Schikora-Rustad, Stine; Vaage, Eline Benno; Mygland, Åse Daasvand; Wergeland, Stig; Aarseth, Jan Harald; Aaberge, Ingeborg Sundsvalen; Torkildsen, Øivind; Holmøy, Trygve; Berge, Tone; Myhr, Kjell-Morten; Harbo, Hanne-Cathrin Flinstad; Andersen, Jan Terje; Munthe, Ludvig Andre; Søraas, Arne Vasli; Celius, Elisabeth Gulowsen; Vaage, John T.; Lund-Johansen, Fridtjof; Nygaard, Gro Owren (Peer reviewed; Journal article, 2021)
      Introduction The effect of disease-modifying therapies (DMT) on vaccine responses is largely unknown. Understanding the development of protective immunity is of paramount importance to fight the COVID-19 pandemic. Objective ...
    • An update on cladribine for relapsing-remitting multiple sclerosis 

      Holmøy, Trygve; Torkildsen, Øivind Fredvik; Myhr, Kjell-Morten (Expert Opinion on Pharmacotherapy;18(15), Journal article; Peer reviewed, 2017-09-11)
      INTRODUCTION: Despite recent progress, currently available therapies for relapsing remitting multiple sclerosis (MS) are only partly effective, and their use is limited by tolerability and safety issues, as well as high ...